HN
Therapeutic Areas
Sumitomo Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| LATUDA® (lurasidone HCl) | Major Depressive Disorder (adjunctive) | Launched / Phase 3 |
| SP-3164 | Non-Hodgkin's Lymphoma | Phase 1/2 |
| DSP-0390 | Recurrent High-Grade Glioma | Phase 1/2 |
| SP-2577 (Seclidemstat) | Sarcomas & Solid Tumors | Phase 1/2 |
| Rexlemestrocel-L | Chronic Low Back Pain | Phase 3 |
| Ansofaxine (TP1) | Major Depressive Disorder | Filed (US) |